Harry L Janssen, Young-Suk Lim, Hyung Joon Kim, Leonard Sowah, Cheng-Hao Tseng, Carla S Coffin, Magdy Elkhashab, Sang Hoon Ahn, Anh-Hoa Nguyen, Diana Chen, Jeffrey J Wallin, Simon P Fletcher, Circe McDonald, Jenny C Yang, Anuj Gaggar, Diana M Brainard, Scott Fung, Yoon Jun Kim, Jia-Horng Kao, Wan-Long Chuang, Anna E Brooks, P Rod Dunbar
BACKGROUND & AIMS: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-like receptor 8 agonist [TLR8]) with tenofovir alafenamide (TAF). METHODS: Viremic patients with CHB not receiving treatment were stratified by HBeAg status and randomized 2:2:1 to TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW), selgantolimod 1...
February 2024: JHEP reports: innovation in hepatology